Abstract
Objective: To evaluate the potential beneficial effects of hawthorn leaf flavonoids (HLF) against polycystic ovary syndrome (PCOS) in a rat model of disease and elucidate the underlying molecular mechanism. Methods: The PCOS model was established by subcutaneous injection of dehydroepiandrosterone (DHEA, 60 mg/kg/day) for 21 consecutive days. HLF (200 mg/kg/day) were orally administered simultaneously or after the injection. The body weight was regularly monitored and recorded. The ovaries were weighed and histologically examined via hematoxylin and eosin staining. The number of follicular cysts was counted under a light microscope. The serous hormones were measured using enzyme-linked immunosorbent assay kits. Insulin resistance (IR) was calculated as HOMA-IR = fasting insulin (µU/L) × fasting glucose (mM)/22.5. The estrous cycle was determined by vaginal smear. The relative expression of tumor necrosis factor-α and interleukin-6 was measured by real-time polymerase chain reaction. The superoxide dismutase activity and malondialdehyde content was determined using commercially available kits. Results: DHEA induced a significant increase of body weight, ovary weight, number of follicular cysts, serous hormones, IR, inflammatory cytokines, and oxidative stress, and it also impaired the estrous cycle. Oral administration of HLF greatly alleviated these complications. Little toxicity of HLF was observed in our rat model. Conclusion: HLF manifest protective effects against PCOS progression in the animal model, which may hold great promise for future clinical applications.
References
1.
Carmina
E
, Lobo
RA
. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women
. J Clin Endocrinol Metab
. 1999
Jun
;84
(6
):1897
–9
.
[PubMed]
0021-972X2.
Goodarzi
MO
, Dumesic
DA
, Chazenbalk
G
, Azziz
R
. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
. Nat Rev Endocrinol
. 2011
Apr
;7
(4
):219
–31
.
[PubMed]
1759-50293.
Teede
H
, Deeks
A
, Moran
L
. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan
. BMC Med
. 2010
Jun
;8
(1
):41
.
[PubMed]
1741-70154.
De Leo
V
, Musacchio
MC
, Cappelli
V
, Massaro
MG
, Morgante
G
, Petraglia
F
. Genetic, hormonal and metabolic aspects of PCOS: an update
. Reprod Biol Endocrinol
. 2016
Jul
;14
(1
):38
.
[PubMed]
1477-78275.
Huang
A
, Brennan
K
, Azziz
R
. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria
. Fertil Steril
. 2010
Apr
;93
(6
):1938
–41
.
[PubMed]
0015-02826.
Strauss
JF
3rd. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome
. Ann N Y Acad Sci
. 2003
Nov
;997
(1
):42
–8
.
[PubMed]
0077-89237.
Mortada
R
, Williams
T
. Metabolic syndrome: polycystic ovary syndrome
. FP Essent
. 2015
Aug
;435
:30
–42
.
[PubMed]
2159-30008.
Sathyapalan
T
, Atkin
SL
. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity
. Mediators Inflamm
. 2010
;2010
:758656
.
[PubMed]
0962-93519.
Legro
RS
, Arslanian
SA
, Ehrmann
DA
, Hoeger
KM
, Murad
MH
, Pasquali
R
, et al.; Endocrine Society
. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline
. J Clin Endocrinol Metab
. 2013
Dec
;98
(12
):4565
–92
.
[PubMed]
0021-972X10.
Moran
LJ
, Ko
H
, Misso
M
, Marsh
K
, Noakes
M
, Talbot
M
, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines
. Hum Reprod Update
. 2013
Sep-Oct
;19
(5
):432
.
[PubMed]
1355-478611.
Lord
JM
, Flight
IH
, Norman
RJ
. Metformin in polycystic ovary syndrome: systematic review and meta-analysis
. BMJ
. 2003
Oct
;327
(7421
):951
–3
.
[PubMed]
0959-813812.
Legro
RS
, Zaino
RJ
, Demers
LM
, Kunselman
AR
, Gnatuk
CL
, Williams
NI
, Dodson
WC
: The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
Am J Obstet Gynecol 2007
;196:402 e401-410; discussion 402 e410-401.13.
Li
Z
, Xu
J
, Zheng
P
, Xing
L
, Shen
H
, Yang
L
, et al. Hawthorn leaf flavonoids alleviate nonalcoholic fatty liver disease by enhancing the adiponectin/AMPK pathway
. Int J Clin Exp Med
. 2015
Oct
;8
(10
):17295
–307
.
[PubMed]
1940-590114.
Fu
JH
, Zheng
YQ
, Li
P
, Li
XZ
, Shang
XH
, Liu
JX
. Hawthorn leaves flavonoids decreases inflammation related to acute myocardial ischemia/reperfusion in anesthetized dogs
. Chin J Integr Med
. 2013
Aug
;19
(8
):582
–8
.
[PubMed]
1672-041515.
Min
Q
, Bai
Y
, Zhang
Y
, Yu
W
, Zhang
M
, Liu
D
, et al. Hawthorn leaf flavonoids protect against diabetes-induced cardiomyopathy in rats via pkc-alpha signaling pathway
. Evid Based Complement Alternat Med
. 2017
;2017
:2071952
.
[PubMed]
1741-427X16.
Jang
M
, Lee
MJ
, Lee
JM
, Bae
CS
, Kim
SH
, Ryu
JH
, et al. Oriental medicine Kyung-Ok-Ko prevents and alleviates dehydroepiandrosterone-induced polycystic ovarian syndrome in rats
. PLoS One
. 2014
Feb
;9
(2
):e87623
.
[PubMed]
1932-620317.
Musso
C
, Shawker
T
, Cochran
E
, Javor
ED
, Young
J
, Gorden
P
. Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth
. Clin Endocrinol (Oxf)
. 2005
Jul
;63
(1
):73
–8
.
[PubMed]
0300-066418.
Diamanti-Kandarakis
E
, Christakou
C
, Kandarakis
H
. Polycystic ovarian syndrome: the commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome
. Minerva Endocrinol
. 2007
Mar
;32
(1
):35
–47
.
[PubMed]
0391-197719.
Sander
V
, Luchetti
CG
, Solano
ME
, Elia
E
, Di Girolamo
G
, Gonzalez
C
, et al. Role of the N, N′-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone
. Reproduction
. 2006
Mar
;131
(3
):591
–602
.
[PubMed]
1470-162620.
Benson
S
, Janssen
OE
, Hahn
S
, Tan
S
, Dietz
T
, Mann
K
, et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome
. Brain Behav Immun
. 2008
Feb
;22
(2
):177
–84
.
[PubMed]
0889-159121.
Amato
G
, Conte
M
, Mazziotti
G
, Lalli
E
, Vitolo
G
, Tucker
AT
, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles
. Obstet Gynecol
. 2003
Jun
;101
(6
):1177
–82
.
[PubMed]
0029-784422.
Guo
R
, Zheng
Y
, Yang
J
, Zheng
N
. Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis
. BMC Genet
. 2015
Jan
;16
(1
):5
.
[PubMed]
1471-215623.
Wu
H
, Yu
K
, Yang
Z
. Associations between TNF-α and interleukin gene polymorphisms with polycystic ovary syndrome risk: a systematic review and meta-analysis
. J Assist Reprod Genet
. 2015
Apr
;32
(4
):625
–34
.
[PubMed]
1058-046824.
Rezvanfar
MA
, Saeedi
S
, Mansoori
P
, Saadat
S
, Goosheh
M
, Shojaei Saadi
HA
, et al. Dual targeting of TNF-α and free radical toxic stress as a promising strategy to manage experimental polycystic ovary
. Pharm Biol
. 2016
;54
(1
):80
–90
.
[PubMed]
1388-020925.
Puder
JJ
, Varga
S
, Nusbaumer
CP
, Zulewski
H
, Bilz
S
, Müller
B
, et al. Women with polycystic ovary syndrome are sensitive to the TNF-alpha-lowering effect of glucose-induced hyperinsulinaemia
. Eur J Clin Invest
. 2006
Dec
;36
(12
):883
–9
.
[PubMed]
0014-297226.
Ghowsi
M
, Khazali
H
, Sisakhtnezhad
S
. Evaluation of TNF-α and IL-6 mRNAs expressions in visceral and subcutaneous adipose tissues of polycystic ovarian rats and effects of resveratrol
. Iran J Basic Med Sci
. 2018
Feb
;21
(2
):165
–74
.
[PubMed]
2008-386627.
Victor
VM
, Rovira-Llopis
S
, Bañuls
C
, Diaz-Morales
N
, Martinez de Marañon
A
, Rios-Navarro
C
, et al. Insulin resistance in pcos patients enhances oxidative stress and leukocyte adhesion: role of myeloperoxidase
. PLoS One
. 2016
Mar
;11
(3
):e0151960
.
[PubMed]
1932-620328.
Kocer
D
, Bayram
F
, Diri
H
. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome
. Gynecol Endocrinol
. 2014
May
;30
(5
):367
–71
.
[PubMed]
0951-3590© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
